Addivant
The results from the most recent toxicology studies, performed in a GLP accredited contract research organization under internationally recognized OECD guidelines, demonstrates no adverse effects at the highest possible concentration levels. Further, in a comparable study, WESTON® 705 is approximately ten times safer than TNPP and three times safer than Tris (2, 4, DTBP) Phosphite, brand names including ALKANOX® 240 and Irgafos® 168.
"This is another important milestone in the commercialization of WESTON® 705, especially at a time when all of us are concerned about the health and safety of the products we are in contact with daily," said John Steitz, Addivant CEO. He added, "We are quite proud of this achievement as many of the largest polymer producers transition to WESTON® 705."
WESTON® 705 is recognized for providing customers with the benefit of superior performance, higher processing productivity and an unprecedented health and safety profile.
About Addivant(TM)
Addivant(TM) is an innovator in the field of polymer additives, developing customized solutions that provide customers enhanced application performance, safe handling, and reduction in cost of use. The company is recognized industry-wide for its extensive portfolio of specialty additives including antioxidants, light stabilizers, rubber additives, polymer modifiers, metal deactivators, polymerization inhibitors and intermediates. Addivant is an international company, with 11 plants in five regions as well as research, manufacturing and sales facilities around the globe. Addivant maintains its global headquarters in Connecticut, USA with regional headquarters in: Al Jubail, Saudi Arabia, Basel, Switzerland, and Shanghai, China. Addivant is an independent portfolio company of SK Capital. Visit www.addivant.com for more information.
Addivant(TM), ALKANOX® 240 and WESTON® 705 are trademarks of Addivant.
Contacts:
Beverly Kindermann
Beverly.Kindermann@addivant.com
Tel: +1 203 702 6182
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/53eef9ea-7e67-4b07-b0fc-182decc391f0
WEB:https://www.addivant.com/
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
CGTN10.8.2025 10:12:03 CEST | Press release
CGTN: 'Dongji Rescue': Humanity forged in blood and fire
Boehringer Ingelheim Limited8.8.2025 21:25:53 CEST | Press release
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
European Investment Bank8.8.2025 18:07:24 CEST | Press release
EIB submits SEC Form 18-K/A Amendment No. 4 - Unaudited Condensed Semi-Annual Financial Statements as at and for the six-month period ended June 30, 2025
European Investment Bank8.8.2025 18:04:10 CEST | Press release
EIB submits Form 18-K/A Amendment No.3 - December 2024 EIB Group Risk Management Disclosure Report
SBM Offshore Amsterdam B.V.8.8.2025 18:01:27 CEST | Press release
FPSO ONE GUYANA producing and on hire
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum